Health · World
US FDA Approves AstraZeneca's New Breast Cancer Drug
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's new breast cancer drug, camizestrant, which will be marketed under the brand name ETCAMAH. The drug is intended for patients with a genetically driven form of metastatic breast cancer. It can be used in combination with other cancer medications. AstraZeneca developed the drug.
How outlets across the spectrum covered it
L 0 C 2 R 0
- Centre (2): Bloomberg, Mint